iTeos Therapeutics Inc (OQ:ITOS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 139 Main Street
CAMBRIDGE MA 02142
Tel: N/A
Website: N/A
IR: N/A
<
Key People
David L. Hallal
Independent Chairman of the Board
Michel Detheux
Chief Executive Officer, Director
Matthew Gall
Chief Financial Officer
Matthew D. Callister
Chief Operating Officer
Yvonne McGrath
Vice President - Research & Development
Joanne Lager
Chief Medical Officer
Business Overview
iTeos Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovery and development of a differentiated immuno-oncology therapeutics for patients. The Company's pipeline includes two clinical-stage programs EOS-448 and EOS-850. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The Company's lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system.
Financial Overview
For the three months ended 31 March 2020, iTeos Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 26% to $6.5M. Higher net loss reflects Research and development expenses increase of 34% to $5.8M (expense), General and administrative expenses increase of 42% to $2.3M (expense), Other expense, net increase of 50% to $42K (expense).
Employees: 46 as of Jun 15, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $688.24M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$29.59M as of Mar 31, 2020
Net annual income (TTM): -$27.88M as of Mar 31, 2020
Free cash flow (TTM): -$18.03M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 33,434,807 as of Jul 24, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.